Lisata Therapeutics (LSTA) Q3 2025 earnings summary

Executive summary

• Achieved key development milestones for certepetide, with positive preliminary and interim results from ASCEND, ILSTA, Sendafox, and CENDIFOX trials, supporting its broad applicability in anti-cancer regimens and solid tumors.

• Entered strategic alliances with GATC Health for AI-driven drug discovery and Catalent for global licensing of certepetide as a SMARTag ADC payload, eligible for up to $10.5 million in milestone payments and revenue sharing.

• Advanced preparations for a global phase III trial of certepetide, pending capital acquisition and partnership.

• Leadership team has extensive experience in biopharmaceutical development, aiming to address unmet medical needs in oncology.

• Cash runway extended into Q1 2027 with no debt, reflecting disciplined expense management.

Financial highlights

• Operating expenses for Q3 2025 were $4.4 million, down 17.3% year-over-year; R&D expenses decreased 22.9% to $2.0 million, and G&A expenses fell 12.1% to $2.5 million.

• Net loss for Q3 2025 was $4.2 million, compared to $4.9 million in Q3 2024; net loss for the nine months ended September 30, 2025 was $13.6 million, down from $15.4 million in the prior year period.

• Revenue for the nine months ended September 30, 2025 was $70,000, related to an upfront license fee.

• Cash and cash equivalents stood at $19.0 million as of September 30, 2025, with working capital of $17.0 million and stockholders' equity of $17.4 million.

• Projected cash runway extends into Q1 2027, excluding costs for a phase III trial.

Outlook and guidance

• Anticipates a data- and transaction-rich period in upcoming quarters, with several key clinical and business milestones expected.

• Final data from ASCEND and ILSTA trials expected in Q1 2026; additional Sendafox, CENDIFOX, and GBM trial data anticipated in 2026.

• Preparation for phase III trial is ongoing, contingent on securing additional funding or partnerships.

• Sufficient cash to fund operations for at least the next 12 months; additional financing likely needed by end of 2026 for long-term needs.

• Ongoing efforts to secure non-dilutive funding, partnerships, and potential equity or debt issuances.